BioXcel Therapeutics Inc. (BTAI) — Research Summary as of August 28, 2026

Overview

BioXcel Therapeutics is a biopharmaceutical company focused on neuroscience and immuno-oncology, utilizing AI-driven drug development approaches [26]. Its lead product is IGALMI (BXCL501), a sublingual film for acute agitation, and it has an oncology pipeline asset, BXCL701, targeting aggressive prostate cancer and other tumors [23][24]. The stock currently trades at approximately $0.72 per share with a market capitalization of roughly $23.79 million, firmly in sub-micro-cap territory [12][13].

---

Key Recent Catalysts (Last ~1–3 Months)